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Decades of progress in developmental cardiology
has advanced our understanding of the early
aspects of heart development, including cardiomyo-
cyte (CM) differentiation. However, control of the
CM maturation that is subsequently required to
generate adult myocytes remains elusive. Here,
we analyzed over 200 microarray datasets from
early embryonic to adult hearts and identified a
large number of genes whose expression shifts
gradually and continuously during maturation. We
generated an atlas of integrated gene expression,
biological pathways, transcriptional regulators, and
gene regulatory networks (GRNs), which show
discrete sets of key transcriptional regulators and
pathways activated or suppressed during CM
maturation. We developed a GRN-based program
named MatStatCM that indexes CM maturation
status. MatStatCM reveals that pluripotent-stem-
cell-derived CMs mature early in culture but are
arrested at the late embryonic stage with aberrant
regulation of key transcription factors. Our study
provides a foundation for understanding CM matu-
ration.INTRODUCTION
The term ‘‘development’’ refers to the process of growing from
an immature pluripotent condition to one of organ-/cell-specific
maturity. Over the past few decades, major advances have been
made in understanding heart development. However, these
efforts mostly focused on early developmental processes such
as cell differentiation and proliferation (Kathiriya et al., 2015;
Kwon et al., 2009; O’Meara et al., 2015; Shenje et al., 2014; Sri-Cell Repvastava, 2006), while control over maturation remains largely
unknown. This lack of the knowledge may be attributed to the
nature of maturation that typically occurs over a long period of
time following terminal differentiation.
The maturation of cardiomyocytes (CMs) initiates at mid-
gestation and continues until adulthood. During this process,
CMs gradually become elongated and rectangular, and the sar-
comeres align and organize (Hirschy et al., 2006; Hoshino et al.,
2012). To propagate electrical activity into the CMs, transverse
tubules (T-tubules) invaginate into the cells during postnatal
development (Di Maio et al., 2007; Ziman et al., 2010). Interca-
lated discs connect CMs to neighboring CMs to allow
simultaneous contraction. Connexin 43 and N-cadherin, key
components of intercalated discs, are expressed in CMs from
early development, but specifically localize to intercalated discs
postnatally (Vreeker et al., 2014). These structures are indispens-
able to CM function. Morphological and structural changes,
coupled with gene expression changes, such as isoform
switches of sarcomere proteins, occur simultaneously, suggest-
ing common transcriptional regulatory mechanisms may control
CM maturation.
Pluripotent stem cells (PSCs) hold great promise for regener-
ative medicine, disease modeling, and drug discovery because
they can differentiate into any cell types in the body with a pa-
tient-specific genetic background. Methods to differentiate of
PSCs in vitro have been reported (Hayashi et al., 2011; Yama-
shita et al., 2000). PSC-derived CMs (PSC-CMs) are among
the most desired and studied cell types as live CMs are rarely
ever obtained from patients. Although PSC-CMs can be effi-
ciently induced from PSCs (Kattman et al., 2011; Uosaki et al.,
2011), proper maturation of PSC-CMs remains a critical hurdle
for recapitulating the adult phenotype. Recent studies have sug-
gested long-term culture, extrinsic stimuli, or culturing on micro-
patterned substratesmay improve cell morphology and enhance
CM maturation (Lundy et al., 2013; Salick et al., 2014; Yanagi
et al., 2007; Yang et al., 2014). However, whether these cells truly
mature for meaningful use as a model for adult-heart diseases
has not been established.orts 13, 1705–1716, November 24, 2015 ª2015 The Authors 1705
Figure 1. Principal Component Analysis of
CM Maturation
(A) Experimental scheme. We obtained cardiac
microarray datasets from GEO, ranging from
early embryonic to adult hearts. Using the data-
sets, we dictated transcriptional landscape of
cardiomyocyte maturation with gene expression
profile, biological function (KEGG pathway), up-
stream transcriptional regulators (using IPA) and
reconstructing GRNs. These analyses were inte-
grated to generate an atlas and prediction of car-
diomyocyte maturation.
(B and C) PCA plots of 213 microarray datasets.
Early embryonic (E8–E11, n = 17, green), mid-
embryonic (E12–E14, n = 39, black), late embry-
onic (E16–E18, n = 26, orange), postnatal (P3–P10,
n = 16, blue), and adult (n = 114, red). (B) Plot of
PC1 and PC2. Linear regression lines for each
stage were shown. Samples were clustered and
aligned through PC1 axis as maturation progress.
(C) Plot of PC2 and PC3. Most of the samples were
clustered and no pattern for maturation was
evident.
(D) Proportion of variances in each principal
component. PC1 and PC 2 represented 60% of
variance in original data.
(E) Box plot of PC1 value for each stage. Box
represents 25th to 75th percentile, mid lines indi-
cate median, and the whiskers show the smallest
to largest values. Outliers (more than 2SD) were
shown as circles.
See also Figure S1 and Table S1.Understanding the transcriptional landscape, including gene
expression profiles, signaling pathways, and upstream tran-
scriptional regulators, has yielded major insights into develop-
ment and disease processes (McKinney-Freeman et al., 2012;
Miller et al., 2014). For instance, earlier cardiac transcriptome
studies revealed a congenital heart disease interactome (Li
et al., 2014) or regulation of CM proliferation and heart regener-
ation (Gan et al., 2015; O’Meara et al., 2015). Recent advances in
bioinformatics have allowed reconstruction of gene regulatory
networks (GRNs) from expression profiles (Cahan et al., 2014;
McKinney-Freeman et al., 2012; Miller et al., 2014). Here, we
examined multi-stage microarray datasets obtained from devel-
oping hearts and generated an atlas of gene expression, path-
ways and transcriptional regulators, and reconstructed GRNs
during CM maturation. We developed a microarray-based pro-
gram that can index CM maturation status, named MatStatCM.
Based on these, we show PSC-CMs undergo maturation early
but this becomes arrested at a late embryonic stage even after
long-term culture. We further identified transcriptional regulators
defective in PSC-CMs that may cause maturation arrest.1706 Cell Reports 13, 1705–1716, November 24, 2015 ª2015 The AuthorsRESULTS
Global Gene Expression Patterns
during Heart Maturation
To assess altered gene expression pat-
terns in developing hearts, we performed
a meta-microarray analysis with datasetsdeposited to Gene Expression Omnibus (GEO). We obtained 39
microarray experiments on the Affymetrix mouse 430 2.0 plat-
form (Table S1) annotated with heart and/or CM, which consist
of 658 microarray datasets. Among the 658, 492 microarray
datasets were directly related to hearts, CMs, and PSCs differ-
entiated toward CMs. We further narrowed the analysis to 213
microarray datasets of wild-type mouse embryos, neonates,
and adults, obtained under normal physiological conditions (Fig-
ure 1A). As the heart is composed of CMs and non-CMs such as
endothelial cells and fibroblasts, we eliminated genes enriched
in non-CMs using purified CM data at mid-embryonic and post-
natal stages (Ieda et al., 2009; 2010), which yielded 17,848
genes.
To analyze overall gene expression patterns of the selected
data, we used principal component analysis (PCA), which is a
standard statistical method to compress and summarize entire
microarray information to two or three dimensions, while retain-
ing most of the expression variation in the data (Figures 1B–1D
and S1) (Raychaudhuri et al., 2000; Ringne´r, 2008). In the PCA
plots (Figures 1B and 1C), respective stages were colored. In
the plot of the first principal component (PC1) and PC2, samples
from each stage were well aligned (Figure 1B). In contrast, in the
plot of PC2 and PC3,most of samples were clustered, and seven
outliers were observed (Figure 1C). PC1 accounted for 40.9% of
variations of the original data (Figure 1D). PC2 and PC3 ac-
counted for 18.7% and 6.8%, respectively. The rest of PCs ac-
counted for <5% (Figure 1D). Given that PC1 accounted for
the major portion of variations, the constant increases in PC1
values from early to late developmental stages (Figures 1B and
1E) suggest that overall gene expression shifts continually in a
unidirectional fashion. Samples from each stage were clustered
to two in PC2 values; however, they may reflect lab-to-lab varia-
tions as samples from a single experiment were clustered to one
side (Figures S1A and S1C). One experiment (GEO: GSE1479)
used atria and ventricles rather than entire hearts. Notably,
both atria and ventricles increased PC1 values at later stages,
implying that maturation-related genes might be similarly regu-
lated in both chambers (Figure S1B). While atria had significantly
lower values than ventricles, this is likely due to the weights of
ventricle-specific genes in calculating PC1 values. These data
suggest that overall gene expression patterns change gradually
over the course of CM maturation.
An Atlas of Temporal Gene Expression and Regulation
during Heart Maturation
Because PCA revealed gradual and unidirectional transcriptional
changes during maturation, we next explored how differentially
regulated genes are involved in biological functions and in turn
how the transcriptional changes are regulated. To this end, we
developed a multilayered atlas of gene expression and regula-
tion, temporal changes of gene expression, pathways, and up-
stream transcriptional regulators from one stage to the next.
First, we selected genes that changed at least 2-fold to the
next stage (p < 0.01); 578 early to mid-embryonic stage, 306
mid- to late embryonic stage, 431 late embryonic to neonatal
stage, and 1,152 neonatal to adult stage genes (Figure 2) were
identified (a full gene list is found in Table S2). In agreement
with PCA observations of gradual and unidirectional changes,
most of the genes continued their expression trends (upregu-
lated or downregulated) throughout the stages, and only small
subsets returned to the baseline at later stages (Figures 2E–2H).
Second, to determine how the genes are involved in CM func-
tion, we used the Kyoto Encyclopedia of Genes and Genomes
(KEGG) pathways enrichment analysis with the genes identified
(Figures 2I–2P; Table S3). We found that the peroxisome prolifer-
ator-activated receptor (PPAR) pathway (mmu03320) is the
only pathway enriched in all comparisons, indicating the activity
of the PPAR pathway increases throughout the maturation.
The cardiac muscle contraction pathway (mmu04260) and car-
diovascular disease pathways, including dilated cardiomyopa-
thy (DCM, mmu05414), hypertrophic cardiomyopathy (HCM,
mmu05410), arrhythmogenic right ventricular cardiomyopathy
(ARVD, mmu05412), and viral myocarditis (mmu05416), contain
structural genes (e.g., sarcomere, desmosome, and sarcoglycan
genes) in different compositions. These cardiac pathways were
enriched in the upregulated group of genes up to the neonatal
stage. However, none of them were enriched in upregulated
genes from neonate to adult, suggesting that the activities ofCell Repthose pathways do not change after the neonatal stage. While
the fatty acid metabolism pathway (mmu00071), which is essen-
tial for the energy supply to adult CMs, was enriched in the
upregulated group of genes during embryonic develop-
ment, carbohydrate metabolism pathways, including glycolysis
(mmu00010), pentose phosphate pathway (mmu00030), fruc-
tose and mannose metabolism (mmu00051), and galactose
metabolisms (mmu00052), were enriched in the group of down-
regulated genes at the neonate stage. From the mid-embryonic
stages, cell-cycle (mmu04110) and its related pathways were
constantly enriched in the group of downregulated genes.
Finally, to determine which upstream transcriptional regula-
tors are involved in maturation in temporal manner, we per-
formed upstream regulator analysis with the ingenuity pathway
analysis (IPA) software (http://www.ingenuit.com). This program
identifies molecular relationships among genes and infers up-
stream regulators with its curated database from published
studies. IPA software calculates an activation Z score of a tran-
scriptional regulator based on the fold change and p value of
genes under the control of the regulator between two groups.
Thus, activation Z scores correspond to activity changes be-
tween the two groups. To assess temporal transcriptional
changes, we used the differentially regulated genes between
one stage and the next as described above for IPA upstream
regulator analysis. Based on this analysis, we identified up-
stream transcriptional regulators activated temporally at each
stage of CM maturation (Figures 2Q–2S). Most of the regulators
changed their activities at one stage or subsequent two stages
(Figures 2Q–2S). While only a small subset of genes identified
in Figures 2A–2D overlapped, there were transcriptional regula-
tors that incrementally changed their activities (Figure 2S). This
suggests that the transcriptional regulators control different
genes at each stage.
Our multilayered and temporal atlas of gene expressions,
pathways, and upstream transcriptional regulators reveals the
process of CM maturation at the transcriptional level.
Development of MatStatCM to Predict Maturation Status
of CMs
A GRN-based method has emerged as a more reliable way for
predicting cell and tissue status than clustering (Cahan et al.,
2014). Thus, we tested if GRNs can be used to predict the status
of CM maturation. To reconstruct stage-specific GRNs of the
heart, we first identified genes that were more predominately ex-
pressed in each stage, using a single dataset, covering all stages
(GEO: GSE51483; Figures S1C and S3A; Table S4) (Li et al.,
2014). Then, to identify the upstream regulators and downstream
targets of these genes, we examined a reported pan cell-type
and tissue GRN (Cahan et al., 2014). While the generic heart
GRN included well-known regulators (e.g., Nkx2-5, Gata4,
Tbx5, andMyocd), stage-specific GRNs included fewer charac-
terized regulators in the heart (Figures 3A–3D). We trained
random forest classifiers for each stagewith expression distribu-
tions estimated from the GSE51483 training dataset. We as-
sessed the performance of the stage-specific classifier by
applying it to independent studies of defined stages of heart
development. We found that theGRN-based classification accu-
rately determined the stage of origin of the profiles and couldorts 13, 1705–1716, November 24, 2015 ª2015 The Authors 1707
(legend on next page)
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detect transition of E15.5 and P7 neonatal heart from earlier to
later stages (Figures 3E–3H).
PSC-CMsMatured to Late Embryonic-Neonatal Stage in
Culture
We next asked whether PSC-CMs mature into adult-like cells
and how mature are they in maturation-enhanced conditions.
Current approaches have not addressed this question, and so
we tested if global gene expression and/or MatStatCM could
determine maturation status of PSC-CMs. To do this, we em-
ployed a long-term culture condition, previously shown to
enhance CM maturation (Lundy et al., 2013; Yanagi et al.,
2007). We differentiated mouse PSCs to CMs and cultured
them for up to 30 days. PSC-CMs began to beat at days 7–8 after
differentiation, and cells were positive for a-actinin, a sarcomere
protein, but did not have clear sarcomere pattern at day 10 (Fig-
ure 4A). At days 20 and 30, sarcomeres were well aligned (Fig-
ure 4A). As mouse PSCs are typically isolated from embryonic
day (E) 3.5 embryos, cultured PSC-CMs at days 10 and 20 are
presumed to be at mid-embryonic and postnatal stages, respec-
tively, if maturation is regulated intrinsically and progresses the
same as its embryonic counterparts.
To assess the maturation status of PSC-CMs cultured in vitro,
we imposed microarray data of PSC-CMs to PCA plot and per-
formed MatStatCM analysis (Figures 4B–4D). With PCA to indi-
cate the global gene expression pattern, PSC-CMs positioned
around early to mid-embryonic stages at day 10 and moved to
late embryonic stage at day 20 (Figure 4B). Notably, PSC-CMs
did not reach to the neonatal stage even at day 30. MatStatCM
classified PSC-CMs at day 10 to early embryonic stage and
PSC-CMs at days 20–30 were classified to mid- to late-embry-
onic stages (Figure 4C). PSC-CMs robustly exhibited the early
embryonic GRN at day 10 and the late embryonic/neonatal
GRN at days 20–30 (Figure 4D). PSC-CMs at days 20–30 also
increased the adult GRN. Compared to the sharp transition of
the GRNs in vivo, the transition of the GRNs in PSC-CMs was
dull, suggesting that their gene expression pattern is not
coherent as that of endogenous CMs. All of these data suggest
that PSC-CMs mature in long-term culture but then arrest at the
late embryonic stage.
To ask if these findings correlate with physiological features,
we used Ca2+ imaging to compare ventricular and atrial CMs
(Figures 4E and 4F). We measured intracellular calcium concen-
tration with Fura-2 dye. We plotted the ratiometry of calcium
bound (380 nm) and unbound (340 mm) Fura-2 was plotted (Fig-Figure 2. Atlas of Transcriptional Landscape during CM Maturation
(A–D) Volcano plots of gene expression changes from one stage to the next.
in red.
(E–H) Time course of changes (log2 fold) of individual genes identified in the vol
decreased one stage to the next, respectively. Black lines indicate mean expres
embryonic hearts. (F) Genes changed from mid to late embryonic hearts. (G) Gen
neonatal to adult hearts.
(I–P) KEGG pathways enriched in the differentially regulated genes (p < 0.05 w
Blue, metabolism; red, cardiac; orange, PPAR; green, cell cycle; black, others.
(M–P) Pathways enriched in downregulated genes at the corresponding stages.
(Q–S) Heatmaps of the activation Z scores of upstream transcriptional regulators, c
stage; blue, lower in later stage. (Q) Transiently activated regulators. (R) Transien
See also Figure S2 and Tables S2 and S3.
Cell Repure 4E), and time-to-peak-50% and time-to-baseline-50% were
used to quantitatively assess velocity of the change in intracel-
lular calcium concentration (Figure 4F). Ventricular CMs dis-
played slow upstroke and downstroke velocities at E12 (238 ±
21 ms and 1,373 ± 42 ms, respectively). Both velocities
increased as maturation progressed (up/down: 54 ± 2/944 ±
48ms at P0, 44 ± 1ms/320 ± 8ms at adult). Atrial CMs displayed
greater velocities than ventricular CMs and did not change dur-
ing embryo development (up/down: 54 ± 5/645 ± 84 ms at E12
and 44 ± 1/613 ± 16 ms at P0). While ventricular CMs displayed
no difference in F/F0, which corresponds to the degree of
change in intracellular calcium concentration, during embryo
development (E12: 17 ± 3 and E18: 20 ± 3), atrial CMs displayed
significant increase in F/F0 (E12: 10 ± 1 and E18: 23 ± 3). Up-
stroke and downstroke velocities of the change in intracellular
calcium concentration in PSC-CMs increased after long-term
culture (up/down: 167 ± 18/1,125 ± 33 at d10, 105 ± 22/760 ±
48 at d20 and 63 ± 10/666 ± 45 at d30). However, while down-
stroke velocities at days 20 and 30 were greater than P0 ventric-
ular CMs, upstroke velocities were still slower. Ca2+ imaging
revealed that PSC-CMs matured to late embryonic/neonate
stages, but their physiological features were incoherent.
Putative Causes of Maturation Arrest In Vitro
PCA, MatStatCM, and physiological experiments showed that in-
vitro-cultured PSC-CMs become similar to the late embryonic
stage CMs but did not progress further. This suggests that genes
are regulated differently in PSC-CMs during their maturation
in vitro. To identify the genes and regulators, we analyzed genes
differentially regulated in PSC-CMs by comparing them to late
embryonic and neonatal hearts and adult hearts. For this anal-
ysis, we focused on the 1,917 genes that were differentially regu-
lated in vivo during maturation. We found that 679 and 571
genes were differentially regulated in day 20–30 PSC-CMs as
compared to late embryonic/neonatal hearts (2-fold difference,
p < 0.01, Figure S3) and adult hearts (at least 4-fold difference,
p < 0.01, Figure S3), respectively. Next, we used IPA to identify
upstream transcriptional regulators showing distinct activities
in PSC-CMs compared to in vivo counterparts. Based on their
activity changes, we further classified the regulators into eight
types (Figure 5). The first four types consisted of regulators
with activities similar to their in vivo counterparts at the late em-
bryonic/neonatal or adult stage (Figure 5, i–iv). The next two
types exhibited higher activities than late embryonic/neonatal
hearts and lower activities than adult hearts and vice versaGenes with >2-fold change and moderate p values of <0.01 were colored
cano plots. Red and blue lines indicate genes with expression increased and
sion changes. Error bars indicate SDs. (E) Genes changed from early to mid-
es changed from late embryonic to neonatal hearts. (H) Genes changed from
as considered as enriched). Text color represents the pathway categories.
(I–L) Pathways enriched in upregulated genes at the corresponding stages.
orrespond to activation changes from one stage to the next. Red, higher in later
tly inactivated regulators. (S) Incrementally changing regulators.
orts 13, 1705–1716, November 24, 2015 ª2015 The Authors 1709
Figure 3. MatStatCM: GRN-Based Prediction System for CM Maturation
(A–D) Stage-specific GRNs. GRNs of early embryonic (A), mid-embryonic (B), late embryonic/neonatal (C) and adult (D) heart. Each node represents a member of
GRN, and factors highlighted in red are transcriptional regulators identified in GRN at each stage. Relationships between regulators and members are shown in
lines. All nodes are listed in Table S4.
(E–H) Assessment of performance with independent datasets from E9 (E, GEO: GSE28186), E13-15 (F, GEO: GSE32078), E18 (G, GEO: GSE8199), and P7-adult
(H, GEO: GSE38754). Each column represents one microarray dataset and classified values of GRN status for each stage were shown as heatmap.
See also Figure S3 and Table S4.
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Figure 4. Maturation of PSC-CMs after
Long-Term Culture
(A) Immunostaining of PSC-CMs with a-actinin at
days 10–30. Scale bar, 20 mm.
(B) PCA of 213 microarray, superimposed with
PSC-CMs at days 10–30.
(C) MatStatCM analysis. GRN status of PSC-CMs
was similar to early embryonic hearts at day 10,
and became mid to late embryonic heart at days
20–30.
(D) GRN statuses of PSC-CMs were assessed
using the GRN classifiers of each maturation
stage. Means + SD are shown (n = 3).
(E) Ca2+ transient of embryonic (E12), neonatal,
adult CMs and PSC-CMs. Cells were stimulated
every 2 s.
(F) Statistics of time (t) to peak 50% and time (t) to
baseline (bl) 50% of Ca2+ transient. Mean + SEM
(nR 9).
Codes for imposing PSC-CM data to PCA and
analyzing with MatStatCM can be found in Data S1.(Figure 5, v and vi). While they were different from their in vivo
counterparts in activity levels, most of their activities shifted
into the right direction: the regulators in the classes were acti-
vated (Figure 5, v) or inactivated (Figure 5, vi) from neonate to
adult (Figure 2). As such, these six types of regulators may not
alter the normal trajectory of maturation in vitro. In contrast,
the last two typeswere the groups of regulators whose transcrip-
tional activities were continuously higher or lower than their
in vivo counterparts throughout the stages (Figure 5, vii and
viii). In particular, regulators incrementally activated throughoutCell Reports 13, 1705–1716, Nothe maturation (Figure 2S) were found
inactive in PSC-CMs (Figure 5, viii,
PPARA/G, PPARGC1A, and CEBPA/B).
Similarly, CTNNB1 was incrementally in-
activated during maturation in vivo, but
remained active in PSC-CMs (Figure 5,
vii). Thus, misregulation of these regula-
tors may be responsible for the aberrant
maturation of PSC-CMs in vitro.
DISCUSSION
In the current study, we (1) developed an
atlas of temporal gene expression, path-
ways, and regulations during heart matu-
ration, and (2) established a method to
determine CM maturation status with
microarray and stage-specific GRNs,
named MatStatCM (Figure 6). With the in-
tegrated approach, we demonstrated
that PSC-CMs can undergo maturation
early but arrest at the late embryonic
stage after long-term culture. We believe
this information will lay the foundation for
understanding CM maturation and be
instrumental for generating adult CMs
from PSCs.This multilayered analysis provides fascinating insights into
understanding CM maturation, which were not demonstrated
in previous studies (Li et al., 2014; Gan et al., 2015; O’Meara
et al., 2015). We found that the atlas of temporal transcriptional
regulations was well correlated with transcriptional and KEGG
pathway changes (Figure 2; Tables S2 and S3). Most of the reg-
ulators were activated or inactivated only once duringmaturation
(Figure 2Q). According to the IPA results, once a regulator was
activated, it remained constantly activated unless inactivated
at later stages (Figure 6A). MEF2C, GATA4, TBX5, MYOCD,vember 24, 2015 ª2015 The Authors 1711
Figure 5. Comparison of Regulator Activ-
ities
Heatmaps showing transcriptional regulator ac-
tivities in PSC-CMs compared to late/neonatal
(left) and adult (right) hearts. Text color represents
activity changes between neonatal and adult
stages. Red, activated; blue, inactivated. Identi-
fied regulators were classified to eight. Venn dia-
gram of classification is shown in the middle. (i–iv)
Transcriptional regulators had activities in PSC-
CMs similar to either late embryonic/neonatal or
adult hearts: (i) similar to adult and higher than late
embryonic/neonatal, (ii) similar to late embryonic/
neonatal and lower than adult, (iii) similar to late
embryonic/neonatal and higher than adult, and (iv)
similar to adult and lower than late embryonic/
neonatal. (v and vi) Transcriptional regulators
had activities in between the in vivo counterparts:
the regulators were activated (v), and inactivated
(vi) from late embryonic/neonate to adult. (vii
and viii) Misregulated transcriptional regulators
in vitro. (vii) Transcriptional regulators had higher
activities in PSC-CMs compared to late embry-
onic/neonatal and adult heart, and (viii) transcrip-
tional regulators had lower activities in PSC-CMs
compared to late embryonic/neonatal and adult
heart.
See also Figure S4.and HIF1A were transiently activated factors from mid- to late
embryos, Among those genes, MEF2C, GATA4, and TBX5
were known as the essential regulators to convert fibroblasts
into CMs in mice, and MYOCD was one of the additional factors
necessary for the conversion in human. These findings suggest
they play important roles in activating cardiac pathways (Ieda
et al., 2010; Wada et al., 2013). However, the cardiac pathways
were also enriched in other stages, suggesting the presence of
alternative regulators (e.g., Regulators in generic GRNs such
as Hopx and Nkx2-5 in the earlier stage, Figure S3). In addition
to the activated regulators, there were inactivated regulators.
For example, Aryl hydrocarbon receptor nuclear translocator
(ARNT) was inactivated at the neonatal stage, suggesting that
the regulator may affect its downstream target genes in embry-
onic hearts. Activation of TP53 and inactivation of MYC cause
cell-cycle arrest and are consistent with the pathway analysis1712 Cell Reports 13, 1705–1716, November 24, 2015 ª2015 The Authorsthat revealed the cell-cycle pathways en-
riched in downregulated genes during the
maturation (Figures 2N–2P; Table S3).
They changed their activities incremen-
tally, and additional cell-cycle repressors,
retinoblastoma 1 (RB1), retinoblastoma-
like 1 (RBL1), and cyclin-dependent ki-
nase inhibitor 2A (CDKN2A) were highly
activated, whereas the cell-cycle accel-
erators, cyclin D1 (CCND1) and E2F1-3
were inactivated in adult. As a result, the
cell-cycle pathway was enriched in
downregulated genes from the earlier
stages, and more cell-cycle-related path-
ways were enriched in downregulatedgenes at the adult stage. Interestingly, the PPAR pathway was
the only pathway enriched in upregulated genes throughout
thematuration. PPAR is considered as amaster regulator of fatty
acid metabolisms (Evans et al., 2004) and it was incrementally
activated through maturation. Pathway analysis also revealed
how metabolic changes are accomplished in vivo. Embryonic
CMs use glycolysis to generate energy, but adult CMs use fatty
acid oxidation (Lopaschuk et al., 1992). During embryonic devel-
opment, fatty acid metabolism pathway was increased, and
glycolysis pathway was decreased upon birth, suggesting that
late embryonic CMs could utilize fatty acid but still they use
glycolysis due to the limited supply of oxygen.
Previous studies reported enhanced PSC-CM maturation in
long-term culture; however, the degree of maturation was un-
known. Our approach with a reference from in vivo maturation
provided a quantitative perspective on CMmaturation, revealing
Figure 6. Summary of the Study
(A and B) Using microarray analysis, we developed an atlas (A) and a prediction method of CM maturation (B). (A) An atlas of CM maturation showing
temporal transcriptional activity and pathway activity changes. (B) Prediction of CM maturation with a GRN-based method, named MatStatCM.
(C) We found that PSC-CMs undergo maturation but are arrested at late embryonic to neonatal stage. There were two groups of transcriptional regula-
tors: (1) the activities of transcriptional regulators were between late embryo/neonate and adult, and (2) too high or too low, compared to the in vivo
counterpart.that PSC-CMs progress through maturation but then are unex-
pectedly arrested at the late embryonic stage after 20 days of
culture (Figures 4, 6B, and 6C). Although the global gene expres-
sion pattern was close to late embryonic or neonatal hearts, the
transition of GRNs was more diffused, and approximately one-
third of the genes differentially regulated during maturation
were misregulated in PSC-CMs. This implies that the activities
of upstream regulators were incoherent in PSC-CMs. Indeed,
approximately half of the upstream transcriptional regulators dis-Cell Repplayed their activities between late embryonic/neonatal and
adult or close to either one, suggesting that they are unlikely
to cause the arrest. The other half were aberrantly active or
inactive as compared to in vivo counterparts, suggesting that
they may be responsible for the abnormal maturation. The aber-
rant regulators include PPARs, PPAR gamma coactivator 1A
(PPARGC1A), CCAAT/enhancer binding protein A/B (CEBPA/B),
and beta-catenin (CTNNB1). It is intriguing to find them active
or inactive because all of them have been implicated in CMorts 13, 1705–1716, November 24, 2015 ª2015 The Authors 1713
maturation: (1) PPARs regulate fatty acid metabolism in heart
and CM-specific deletion of PPARs results cardiac diseases
such as cardiomyopathy and hypertrophy (Ahmadian et al.,
2013; Finck, 2007), (2) PPARGC1A/B, coactivators of PPARs,
and other nuclear receptors, regulate mitochondrial biogenesis
in heart (Lehman et al., 2000), (3) CEBPB inhibits CM prolifera-
tion and hypertrophy (Bostro¨m et al., 2010), (4) activation of
CTNNB1 increases CM proliferation and causes sarcomere
disarray, suggesting that CTNNB1 alters CM maturation (Tseng
et al., 2006; Uosaki et al., 2013), and (5) to recapitulate ARVD,
an adult-onset heart disease with pathogenic fatty acid infiltra-
tion in CMs and CM loss, with patient-derived hPSC-CMs,
a cocktail of chemicals including dexamethasone (NR3C1/
glucocorticoid receptor) and Rosiglitazone (PPARD), was used
to create a lipogenic condition (Kim et al., 2013). Further
studies will be necessary to determine their roles for PSC-CM
maturation.
Our method can be applied to the other culture conditions
known to enhance CM maturation: long-term culture, supple-
mentation of factors (e.g., thyroid hormone), micro-patterning,
and electrical and mechanical stimulation were reported to
enhance CM maturation (Chan et al., 2013; Nunes et al., 2013;
Salick et al., 2014; Yang et al., 2014). As no tool has been avail-
able for maturation analysis, it was almost impossible to
compare and determine which maturation method is better
and how mature the CMs are in each study. MatStatCM can be
a powerful tool to compare and determine CMmaturation status,
as it is a computer program designed to inform the transcrip-
tional status of CM maturation in a non-biased fashion, devel-
oped based on well-standardized microarray platform, and
running on statistical software R (Figure 3; see Data S1 for codes
and datasets). The limitation of MatStatCM is that the current
version only supports the mouse 430 2.0 microarray chip due
to the limited number and time points of microarray datasets
conducted with other chips, such as newer mouse gene 1.0
ST, chips for human genes and RNA sequencing (RNA-seq).
We expect to update/upgrade the prediction program as more
information becomes available.
The current study utilized bioinformatics to determine tran-
scriptional networks and regulators during CM maturation.
Thus, it will be important to investigate expression kinetics of
each transcriptional regulator and its target genes by biochem-
ical methods, such as chromatin immunoprecipitation. Similar to
transcriptional regulators, microRNAs (miRNAs) also regulate a
large number of genes with specific biological functions (He
and Hannon, 2004) and were implicated in CM maturation. For
instance, conditional knockout of Dicer1, a key regulator of
miRNA biogenesis, in the embryonic heart resulted in dilated
cardiomyopathy-like phenotypes with misexpression of cardiac
contractile proteins and profound sarcomere disarray, sug-
gesting that miRNAs are involved in maintaining CMs (Chen
et al., 2008; da Costa Martins et al., 2008). Given that several
miRNAs are involved in CM proliferation and maturation (Cao
et al., 2013; Eulalio et al., 2012; Kuppusamy et al., 2015), it will
be interesting to study if the transcriptional regulators identified
in this research affect maturation-related miRNAs. It would also
be important to investigate the role of miRNAs during CM
maturation.1714 Cell Reports 13, 1705–1716, November 24, 2015 ª2015 The AuEXPERIMENTAL PROCEDURES
Microarray Analysis
Microarray analysis used the statistical software Bioconductor R (Gentleman
et al., 2004; Huber et al., 2015).We obtained 658 datasets annotatedwith heart
and/or CMs from GEO. List of datasets and a brief description are found in
Table S1. We performed frozen robust multi-array average (fRMA) (McCall
et al., 2010) to normalized the datasets. To convert probe sets to each gene,
we selected a probe-set with widest dynamic range (Seita et al., 2012).
We eliminated non-CM-enriched genes in heart (1.5-fold and moderated
p value <0.05: 3,000 genes) (Ieda et al., 2009, 2010). Principal component
analysis (PCA) was performed using R function prcomp with standard condi-
tion. We used empirical Bayes (limma package) to compare expressions
among samples (Ritchie et al., 2015), and thresholds for fold change and
moderated p value were determined in the main text and figure legends. Heat-
maps were generated using the R function pheatmap. For Kyoto Encyclopedia
of Genes and Genomes (KEGG) pathway analysis, we use DAVID Bioinformat-
ics Database (Huang et al., 2009b; 2009a). To infer upstream regulators, we
used ingenuity pathway analysis (IPA) (http://www.ingenuit.com). To recon-
struct stage-specific GRNs of the heart and assess GRN status, we used
pan cell-type and tissue GRNs and the calculation method that has been
described and validated (Cahan et al., 2014). Source codes and datasets for
PCA, GRN reconstruction, and MatStatCM can be found in Data S1. Codes
for CellNet, which are required for GRN reconstruction and MatStatCM, are
available through github (https://github.com/pcahan1/CellNet).
PSC Culture and Cardiac Differentiation
Mouse PSCs with a cardiac-specific Ncx1 promoter-driven puromycin resis-
tance gene (Yamanaka et al., 2008) were maintained in 2i medium (Glasgow
minimum essential medium with 10% fetal bovine serum, 1,000 U/ml ESGRO
[Millipore], 3 mM CHIR99021, 1 mM PD0325901, Glutamax, sodium pyruvate,
and MEM non-essential amino acids) (Uosaki et al., 2012). For cardiac differ-
entiation, cells were suspended in serum-free differentiation medium (SFD)
(Iscove’s modified Dulbecco’s medium and F-2 medium, supplemented with
B27, N2, Glutamax, ascorbic acid, and 1-thyolglycerol) (Kattman et al.,
2011) for 2 days. Cells were subsequently treatedwith Activin A, bonemorpho-
genetic protein 4 (BMP4), and vascular endothelial growth factor (VEGF) for
2 days. Then, cell clusters were dissociated and replated with basic fibroblast
growth factor (bFGF), FGF10, and VEGF for 3 more days. By day 7 after differ-
entiation, cells start self-beating. To eliminate non-cardiac cells, we added pu-
romycin for 2–3 days. At days 9–10, we analyzed CMpurity by cardiac troponin
T staining (Uosaki et al., 2011) and cells with at least 90% purity were used for
further analysis. For long-term culture, we replated differentiated cells at day 9
and cultured up to 30 days after differentiation in SFD medium.
Immunostaining
For immunostaining, cells were cultured in chamber slide, fixed with 4% para-
formaldehyde for overnight, washed with PBS, permeabilized with PBS-Triton
X, blocked with 3% BSA in PBS, and incubated with anti-a-actinin antibody
(1:500, Sigma-Aldrich) for overnight. Cells were washed and stained with sec-
ondary antibody, anti-mouse IgG (1:500, Invitrogen) conjugated with Alexa-
Fluor dye (Invitrogen). DNA was stained with DAPI. Images were taken with
a confocal microscope (Leica TCS SPE RGBV).
RNA Purification and Microarray
RNA was isolated from cells using TRIzol following manufacturer instruction
and then submitted to microarray core at Johns Hopkins University. The
accession number for the full dataset of PSC-CMs reported in this paper is
GEO: GSE73233.
Ca2+ Transient
To analyze Ca2+ transient with embryonic and postnatal CMs, hearts were
minced and enzymatically dissociated with collagenase and trypsin. Cells
were then seeded on gelatin or laminin-coated cover glasses in SFD medium
supplemented with 10% serum and analyzed the following day. Adult CMs
were isolated with Langendorff perfusion and used in the same day (Seo
et al., 2014). All mouse procedures were reviewed and approved by the Johnsthors
Hopkins University. PSC-CMs were differentiated as described above and
then replated at day 9 for the experiments at day 10 or replated around day
15 for the experiments at day 20 and 30. To assess cytosolic Ca2+, cells
were loaded with Fura-2 dye in Tyrode’s solution for 20 min. Cytosolic Ca2+
was monitored with IonOptix system, using excitation wavelengths of 340
and 380 nm to detect Fura-2 fluorescence at 510 nm. Cells were stimulated
every 2 s.
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